|0.53|| -0.03 / -5.36%|
Provectus Biopharmaceuticals, Inc. manufactures prescription drugs, medical device systems and counter products. It is a development-stage biopharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company developing and intend to license or market and sell their two prescription drug candidates, PV-10, which is for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer; and PH-10, which provides minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. Through its subsidiaries, hold patents and other intellectual property related to OTC products and non-core technologies. Provectus Biopharmaceuticals was founded on January 17, 2002 and is headquartered in Knoxville, TN.
|H. Craig Dees||Chairman & Chief Executive Officer|
|Timothy C. Scott||President & Director|
|Peter R. Culpepper||COO, CFO, Secretary & Treasure|
|Eric A. Wachter||Chief Technology Officer|
|Bill Gordon||Head-Media Relations|